89 results on '"Edeas M"'
Search Results
2. Les polyphénols et les polyphénols de thé
- Author
-
Edeas, M.
- Published
- 2007
- Full Text
- View/download PDF
3. La curcumine
- Author
-
Edeas, M.
- Published
- 2006
- Full Text
- View/download PDF
4. Comparison of oxidized low-density lipoprotein toxicity on EA.hy 926 cells and human vein endothelial cells: influence of antioxidant systems
- Author
-
Claise, C., Chalas, J., Edeas, M., Abella, A., Khalfoun, Y., Laurent, D., and Lindenbaum, A.
- Published
- 1997
- Full Text
- View/download PDF
5. Les antioxydants dans la tourmente
- Author
-
Edeas, M.
- Published
- 2005
- Full Text
- View/download PDF
6. Neurodegenerative diseases and oxidative stress
- Author
-
Emerit, J., Edeas, M., and Bricaire, F.
- Published
- 2004
- Full Text
- View/download PDF
7. Could antioxidant supplementation reduce antiretroviral therapy-induced chronic stable hyperlactatemia?
- Author
-
Lopez, O., Bonnefont-Rousselot, D., Edeas, M., Emerit, J., and Bricaire, F.
- Published
- 2003
- Full Text
- View/download PDF
8. Les crampes musculaires en dialyse sous citrate sont liées à une altération de l’activité mitochondriale et de la qualité du microbiote
- Author
-
Durand, P.-Y., primary, Edeas, M., additional, Attaf, D., additional, Seret, G., additional, and Menoyo-Calonge, V., additional
- Published
- 2019
- Full Text
- View/download PDF
9. Effect of ethyl esterification of phenolic acids on low-density lipoprotein oxidation
- Author
-
Chalas, J., Claise, C., Edeas, M., Messaoudi, C., Vergnes, L., Abella, A., and Lindenbaum, A.
- Published
- 2001
- Full Text
- View/download PDF
10. Citroflavonoïdes
- Author
-
Edeas, M.
- Published
- 2007
- Full Text
- View/download PDF
11. Targeting microbiota-mitochondria inter-talk: Microbiota control mitochondria metabolism
- Author
-
Yann Saint-Georges-Chaumet, Attaf D, Pelletier E, Edeas M, Unité de Biotechnologie, Biocatalyse et Biorégulation (U3B), and Université de Nantes (UN)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Fatty Acids ,[SDV.BC.BC]Life Sciences [q-bio]/Cellular Biology/Subcellular Processes [q-bio.SC] ,Nitric Oxide ,digestive system ,Gastrointestinal Microbiome ,Mitochondria ,Gastrointestinal Tract ,Oxidative Stress ,stomatognathic diseases ,fluids and secretions ,Humans ,Hydrogen Sulfide ,Reactive Oxygen Species ,Oxidation-Reduction - Abstract
International audience; Our aim is to highlight the subtle relationship that exists between microbiota and mitochondria. Microbiota targets mitochondria by modulating the Reactive Oxygen Species (ROS) production and the mitochondrial activity through interactions with toxins, proteins or other metabolites released by gut microbiota. The intriguing relationship that exists between mitochondria and microbiota is strengthened by the probable prokaryotic origin of mitochondria. Emerging data implicates a role for ROS, nitric oxide, Short Chain Fatty Acids and hydrogen sulfide in the cross-talk between microbiota - mitochondria and REDOX signaling. Several studies have shown that microbiota act and modulate mitochondrial activity, and use it as a relay to strengthen host-microbiotal interaction. This modulation depends on the gut bacterial strain quality and diversity to increase its pathogenic versus beneficial effects. Furthermore, based on conclusions from new studies, it is possible that microbiota can directly interact with the host cell gene expression by favoring bacterial and mitochondrial DNA insertion in the nuclear genome. The emerging knowledge of mitochondria-microbiota interaction may be of great importance to better understand the mechanism of mitochondrial and metabolic diseases, and the syndromes associated with change in quality and quantity of microbiotal species. We suggest that microbiota via mitochondrial modulation influence cell homeostasis and metabolism. The challenge will be to find strategies to modulate the quality and diversity of microbiota rather than acting on microbiota metabolites and microbiota related factors. The medicine of tomorrow will be completely personalized. Firstly there will be a test to show the quality, quantity and diversity of microbiota, and secondly a preventive or therapeutic strategy will be administrated (probiotics, diet, prodrug or fecal transplantation). The era of digital medicine is here.
- Published
- 2015
12. In vivo visualization and quantification of mitochondrial morphology in C. elegans
- Author
-
Smith, R.L., De Vos, W.H., de Boer, R., Manders, E.M.M., van der Spek, H., Weissig, V., Edeas, M., Molecular Biology and Microbial Food Safety (SILS, FNWI), and Molecular Cytology (SILS, FNWI)
- Subjects
In vivo ,Veterinary medicine ,Model system ,Mitochondrion ,Biology ,biology.organism_classification ,Drug toxicity ,Cytometry ,Mitochondrial morphology ,Caenorhabditis elegans ,Visualization ,Cell biology - Abstract
Caenorhabditis elegans is a highly malleable model system, intensively used for functional, genetic, cytometric and integrative studies. Due to its simplicity and large muscle cell number, C. elegans has frequently been used to study mitochondrial deficiencies caused by disease or drug toxicity. Here we describe a robust and efficient method to visualize and quantify mitochondrial morphology in vivo. This method has many practical and technical advantages above traditional (manual) methods and provides a comprehensive analysis of mitochondrial morphology.
- Published
- 2015
13. Comparaison de l’acétate de calcium au carbonate de calcium : étude multicentrique
- Author
-
Brunet, P., primary, Juillard, L., additional, Attaf, D., additional, and Edeas, M., additional
- Published
- 2015
- Full Text
- View/download PDF
14. Oncolyn's Anti-Cancer, Anti-Aging and Other Cytoprotective Functions
- Author
-
Djang, A. H. K., Nelson, M. B., Zhou, D. Y., Edeas, M., Zhang, Z. S., Zhang, Y. L., Lai, Z. S., Lan, L., Adams, M., Sun, H., Zhang, Y. S., Yang, P. M., Lin, G. L., Taylor, C., Galaris, D., Pelletier, G., Lafontaine, L., and Laderoute, M.
- Abstract
Anticancer Res
- Published
- 2004
15. Maillard Reaction, mitochondria and oxidative stress: Potential role of antioxidants
- Author
-
Edeas, M., primary, Attaf, D., additional, Mailfert, A.-S., additional, Nasu, M., additional, and Joubet, R., additional
- Published
- 2010
- Full Text
- View/download PDF
16. The Maillard reaction, its nutritional and physiopathological aspects. Introduction
- Author
-
Edeas, M., primary and Robert, L., additional
- Published
- 2010
- Full Text
- View/download PDF
17. Curcumin
- Author
-
Edeas, M., primary
- Published
- 2006
- Full Text
- View/download PDF
18. S.4.2 Neurodegenerative diseases and oxidative stress
- Author
-
Emerit, J., primary and Edeas, M., additional
- Published
- 2005
- Full Text
- View/download PDF
19. Could antioxidant supplementation reduce antiretroviral therapy-induced chronic stable hyperlactatemia?
- Author
-
Lopez, O, Bonnefont-Rousselot, D, and Edeas, M
- Subjects
Antioxidants -- Health aspects -- Complications and side effects ,Highly active antiretroviral therapy -- Health aspects ,Health ,Complications and side effects ,Health aspects - Abstract
Lopez O, Bonnefont-Rousselot D, Edeas M, et al. Biomed Pharrnacother 2003;57:113-116. Objective.--To determine if asymptomatic stable chronic hyperlactatemia in human immunodeficiency virus (HIV)-infected patients under highly active antiretroviral therapy (HAART, [...]
- Published
- 2003
20. Recent developments in mitochondrial medicine (part 2)
- Author
-
Weissig Volkmar and Edeas Marvin
- Subjects
mitochondrial medicine ,aging ,microbiota ,covid-19 ,humanin ,reactive oxygen species ,Medicine ,Science - Abstract
Called “bioblasts” in 1890, named “mitochondria” in 1898, baptized in 1957 as the “powerhouse of the cell” and christened in 1999 as the “motor of cell death”, mitochondria have been anointed in 2017 as “powerhouses of immunity”. In 1962, for the first time a causal link between mitochondria and human diseases was described, the genetic basis for which was revealed in 1988. The term “mitochondrial medicine” was coined in 1994. Research into mitochondria has been conducted ever since light microscopic studies during the end of the 19th century revealed their existence. To this day, new discoveries around this organelle and above all new insights into their fundamental role for human health and disease continue to surprise. Nowadays hardly any disease is known for which either the etiology or pathogenesis is not associated with malfunctioning mitochondria. In this second part of our review about recent developments in mitochondrial medicine we continue tracking and highlighting selected lines of mitochondrial research from their beginnings up to the present time. Mainly written for readers not familiar with this cell organelle, we hope both parts of our review will substantiate what we articulated over a decade ago, namely that the future of medicine will come through better understanding of the mitochondrion.
- Published
- 2022
- Full Text
- View/download PDF
21. Phenylarsine oxide inhibits ex vivo HIV-1 expression
- Author
-
Arbault, S, primary, Edeas, M, additional, Legrand-Poels, S, additional, Sojic, N, additional, Amatore, C, additional, Piette, J, additional, Best-Belpomme, M, additional, Lindenbaum, A, additional, and Vuillaume, M, additional
- Published
- 1997
- Full Text
- View/download PDF
22. Inhibition of lung epithelial cell proliferation by hyperoxia. Posttranscriptional regulation of proliferation-related genes.
- Author
-
Clement, A, primary, Edeas, M, additional, Chadelat, K, additional, and Brody, J S, additional
- Published
- 1992
- Full Text
- View/download PDF
23. Recent developments in mitochondrial medicine (Part 1)
- Author
-
Weissig Volkmar and Edeas Marvin
- Subjects
biochemistry ,cells ,dqasome ,lipoplexe ,heteroplasmy ,mirna ,mitochondrial medicine ,mitochondrial diseases ,mitochondrial dna ,mitochondrial dysfunction ,mitochondrial research ,mitochondrion ,mitochondrium ,mitomirs ,mtdna ,organelle ,physiology ,pna ,research ,science ,Medicine ,Science - Abstract
Research into elucidating structure and function of mitochondria has been quite steady between the time of discovery during the end of the 19th century until towards the late 1980’s. During the 1990s there was talk about a “comeback” of this organelle reflecting a widely revitalized interest into mitochondrial research which was based on two major discoveries made during that time. The first was the etiological association between human diseases and mitochondrial DNA mutations, while the second revealed the crucial function of mitochondria during apoptosis. The March 5th, 1999 issue of Science even featured a textbook image of a mitochondrion on its front cover and was entirely dedicated to this organelle. Whilst the term “comeback” might have been appropriate to describe the general excitement surrounding the new mitochondrial discoveries made during the 1990s, a term for describing the progress made in mitochondrial research during the last two decades is difficult to find. Between 2000 and 2020 the number of publications on mitochondria has skyrocketed. It is now widely accepted that there hardly exists any human disease for which either the etiology or pathogenesis does not seem to be associated with mitochondrial malfunction. In this review we will discuss and follow several lines of mitochondrial research from their early beginnings up to the present. We hope to be able to convince the reader of what we expressed about a decade ago, that the future of medicine will come through mitochondria.
- Published
- 2021
- Full Text
- View/download PDF
24. Oxidized-LDL induce apoptosis in HUVEC but not in the endothelial cell line EA.hy 926
- Author
-
Claise, C., Edeas, M., Chaouchi, N., Chalas, J., Capel, L., Kalimouttou, S., Vazquez, A., and Lindenbaum, A.
- Published
- 1999
- Full Text
- View/download PDF
25. Oxidized low-density lipoprotein induces the production of interleukin-8 by endothelial cells
- Author
-
Claise, C., Edeas, M., Chalas, J., Cockx, A., Abella, A., Capel, L., and Lindenbaum, A.
- Published
- 1996
- Full Text
- View/download PDF
26. Investigation of Mitochondrial Via Immunofluorescence
- Author
-
Hopp, Ann-Katrin, Hottiger, Michael O, University of Zurich, Weissig, V, Edeas, M, and Hottiger, Michael O
- Subjects
1311 Genetics ,1312 Molecular Biology ,570 Life sciences ,biology ,10226 Department of Molecular Mechanisms of Disease - Published
- 2021
27. Reduced HDL-cholesterol in long COVID-19: A key metabolic risk factor tied to disease severity.
- Author
-
Al-Zadjali J, Al-Lawati A, Al Riyami N, Al Farsi K, Al Jarradi N, Boudaka A, Al Barhoumi A, Al Lawati M, Al Khaifi A, Musleh A, Gebrayel P, Vaulont S, Peyssonnaux C, Edeas M, and Saleh J
- Subjects
- Humans, Cholesterol, HDL, Risk Factors, Ferritins, Patient Acuity, Chronic Disease, Post-Acute COVID-19 Syndrome, COVID-19
- Abstract
This controlled study investigated metabolic changes in non-vaccinated individuals with Long-COVID-19, along with their connection to the severity of the disease. The study involved 88 patients who experienced varying levels of initial disease severity (mild, moderate, and severe), and a control group of 29 healthy individuals. Metabolic risk markers from fasting blood samples were analyzed, and data regarding disease severity indicators were collected. Findings indicated significant metabolic shifts in severe Long-COVID-19 cases, mainly a marked drop in HDL-C levels and a doubled increase in ferritin levels and insulin resistance compared to the mild cases and controls. HDL-C and ferritin were identified as the leading factors predicted by disease severity. In conclusion, the decline in HDL-C levels and rise in ferritin levels seen in Long-COVID-19 individuals, largely influenced by the severity of the initial infection, could potentially play a role in the persistence and progression of Long-COVID-19. Hence, these markers could be considered as possible therapeutic targets, and help shape preventive strategies to reduce the long-term impacts of the disease., Competing Interests: Conflicts of interest The authors declare no conflicts of interest., (Copyright © 2024 HCFMUSP. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
28. Host and microbiota derived extracellular vesicles: Crucial players in iron homeostasis.
- Author
-
Daou Y, Falabrègue M, Pourzand C, Peyssonnaux C, and Edeas M
- Abstract
Iron is a double-edged sword. It is vital for all that's living, yet its deficiency or overload can be fatal. In humans, iron homeostasis is tightly regulated at both cellular and systemic levels. Extracellular vesicles (EVs), now known as major players in cellular communication, potentially play an important role in regulating iron metabolism. The gut microbiota was also recently reported to impact the iron metabolism process and indirectly participate in regulating iron homeostasis, yet there is no proof of whether or not microbiota-derived EVs interfere in this relationship. In this review, we discuss the implication of EVs on iron metabolism and homeostasis. We elaborate on the blooming role of gut microbiota in iron homeostasis while focusing on the possible EVs contribution. We conclude that EVs are extensively involved in the complex iron metabolism process; they carry ferritin and express transferrin receptors. Bone marrow-derived EVs even induce hepcidin expression in β-thalassemia. The gut microbiota, in turn, affects iron homeostasis on the level of iron absorption and possibly macrophage iron recycling, with still no proof of the interference of EVs. This review is the first step toward understanding the multiplex iron metabolism process. Targeting extracellular vesicles and gut microbiota-derived extracellular vesicles will be a huge challenge to treat many diseases related to iron metabolism alteration., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Daou, Falabrègue, Pourzand, Peyssonnaux and Edeas.)
- Published
- 2022
- Full Text
- View/download PDF
29. Microbiota medicine: towards clinical revolution.
- Author
-
Gebrayel P, Nicco C, Al Khodor S, Bilinski J, Caselli E, Comelli EM, Egert M, Giaroni C, Karpinski TM, Loniewski I, Mulak A, Reygner J, Samczuk P, Serino M, Sikora M, Terranegra A, Ufnal M, Villeger R, Pichon C, Konturek P, and Edeas M
- Subjects
- Dysbiosis therapy, Gastrointestinal Tract, Humans, Prebiotics, Gastrointestinal Microbiome, Microbiota, Probiotics therapeutic use
- Abstract
The human gastrointestinal tract is inhabited by the largest microbial community within the human body consisting of trillions of microbes called gut microbiota. The normal flora is the site of many physiological functions such as enhancing the host immunity, participating in the nutrient absorption and protecting the body against pathogenic microorganisms. Numerous investigations showed a bidirectional interplay between gut microbiota and many organs within the human body such as the intestines, the lungs, the brain, and the skin. Large body of evidence demonstrated, more than a decade ago, that the gut microbial alteration is a key factor in the pathogenesis of many local and systemic disorders. In this regard, a deep understanding of the mechanisms involved in the gut microbial symbiosis/dysbiosis is crucial for the clinical and health field. We review the most recent studies on the involvement of gut microbiota in the pathogenesis of many diseases. We also elaborate the different strategies used to manipulate the gut microbiota in the prevention and treatment of disorders. The future of medicine is strongly related to the quality of our microbiota. Targeting microbiota dysbiosis will be a huge challenge., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
30. Low transferrin levels predict heightened inflammation in patients with COVID-19: New insights.
- Author
-
Claise C, Saleh J, Rezek M, Vaulont S, Peyssonnaux C, and Edeas M
- Subjects
- Biomarkers, C-Reactive Protein metabolism, Humans, Inflammation, SARS-CoV-2, COVID-19 diagnosis, Transferrin analysis, Transferrin metabolism
- Abstract
Objectives: Mounting evidence links hyperinflammation in gravely ill patients to low serum iron levels and hyperferritinemia. However, little attention has been paid to other iron-associated markers such as transferrin. The aim of this study was to investigate the association of different iron parameters in severe COVID-19 and their relation to disease severity., Subjects and Methods: This study involved 73 hospitalized patients with positive test results for SARS-CoV-2. Patients were classified into two groups according to symptom severity: mild and severe. Blood levels of anti-SARS-CoV-2 antibodies, interleukin 6 (IL-6), C-reactive protein (CRP), and iron-related biomarkers were measured., Results: The results revealed a significant increase in IL-6, CRP, and ferritin levels and decreased transferrin and iron levels in severe COVID-19. Transferrin negatively predicted variations in IgM and IgG levels (P < 0.001), as well as 34.4% and 36.6% increase in IL-6 and CRP levels, respectively (P < 0.005). Importantly, transferrin was the main negative predictor of ferritin levels, determining 22.7% of serum variations (P < 0.001)., Conclusion: Reduced serum transferrin and iron levels, along with the increased CRP and high ferritin, were strongly associated with the heightened inflammatory and immune state in COVID-19. Transferrin can be used as a valuable predictor of increased severity and progression of the disease., Competing Interests: Conflict of interest The authors declare no conflict of interest., (Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
31. Recent Advances in Research on Polyphenols: Effects on Microbiota, Metabolism, and Health.
- Author
-
Rajha HN, Paule A, Aragonès G, Barbosa M, Caddeo C, Debs E, Dinkova R, Eckert GP, Fontana A, Gebrayel P, Maroun RG, Napolitano A, Panzella L, Pasinetti GM, Stevens JF, Schieber A, and Edeas M
- Subjects
- Antioxidants pharmacology, Functional Food, Polyphenols metabolism, Polyphenols pharmacology, Gastrointestinal Microbiome, Microbiota
- Abstract
Polyphenols have attracted huge interest among researchers of various disciplines because of their numerous biological activities, such as antioxidative, antiinflammatory, antiapoptotic, cancer chemopreventive, anticarcinogenic, and antimicrobial properties, and their promising applications in many fields, mainly in the medical, cosmetics, dietary supplement and food industries. In this review, the latest scientific findings in the research on polyphenols interaction with the microbiome and mitochondria, their metabolism and health beneficial effects, their involvement in cognitive diseases and obesity development, as well as some innovations in their analysis, extraction methods, development of cosmetic formulations and functional food are summarized based on the papers presented at the 13th World Congress on Polyphenol Applications. Future implications of polyphenols in disease prevention and their strategic use as prophylactic measures are specifically addressed. Polyphenols may play a key role in our tomorrow´s food and nutrition to prevent many diseases., (© 2021 The Authors. Molecular Nutrition & Food Research published by Wiley-VCH GmbH.)
- Published
- 2022
- Full Text
- View/download PDF
32. Mitochondrial Dysfunction in Mitochondrial Medicine: Current Limitations, Pitfalls, and Tomorrow.
- Author
-
Gueguen N, Lenaers G, Reynier P, Weissig V, and Edeas M
- Subjects
- Animals, Biosensing Techniques methods, Energy Metabolism, Humans, Metabolomics methods, Mitochondria metabolism, Mitochondria pathology, Mitochondrial Diseases metabolism, Mitochondrial Diseases pathology
- Abstract
Until recently restricted to hereditary mitochondrial diseases, mitochondrial dysfunction is now recognized as a key player and strategic factor in the pathophysiological of many human diseases, ranging from the metabolism, vascular, cardiac, and neurodegenerative diseases to cancer. Because of their participation in a myriad of cellular functions and signaling pathways, precisely identifying the cause of mitochondrial "dysfunctions" can be challenging and requires robust and controlled techniques. Initially limited to the analysis of the respiratory chain functioning, these analytical techniques now enlarge to the analyses of mitochondrial and cellular metabolism, based on metabolomic approaches.Here, we address the methods used to assay mitochondrial dysfunction, with a highlight on the techniques used in diagnosis on tissues and cells derived from patients, the information they provide, and their strength and weakness.Targeting mitochondrial dysfunction by various strategies is a huge challenge, requires robust methods of evaluation, and should be able to take into consideration the mitochondria dynamics and localization. The future of mitochondrial medicine is strongly related to a perfect comprehension of its dysfunction.
- Published
- 2021
- Full Text
- View/download PDF
33. Mitochondria and microbiota dysfunction in COVID-19 pathogenesis.
- Author
-
Saleh J, Peyssonnaux C, Singh KK, and Edeas M
- Subjects
- Blood Coagulation Disorders etiology, Blood Platelets, COVID-19, Cardiolipins metabolism, Dysbiosis pathology, Homeostasis, Humans, Inflammation metabolism, Iron, Oxidative Stress, Pandemics, SARS-CoV-2, Thrombocytopenia, Betacoronavirus, Coronavirus Infections complications, Mitochondria metabolism, Mitochondrial Diseases virology, Pneumonia, Viral complications
- Abstract
The COVID-19 pandemic caused by the coronavirus (SARS-CoV-2) has taken the world by surprise into a major crisis of overwhelming morbidity and mortality. This highly infectious disease is associated with respiratory failure unusual in other coronavirus infections. Mounting evidence link the accelerated progression of the disease in COVID-19 patients to the hyper-inflammatory state termed as the "cytokine storm" involving major systemic perturbations. These include iron dysregulation manifested as hyperferritinemia associated with disease severity. Iron dysregulation induces reactive oxygen species (ROS) production and promotes oxidative stress. The mitochondria are the hub of cellular oxidative homeostasis. In addition, the mitochondria may circulate "cell-free" in non-nucleated platelets, in extracellular vesicles and mitochondrial DNA is found in the extracellular space. The heightened inflammatory/oxidative state may lead to mitochondrial dysfunction leading to platelet damage and apoptosis. The interaction of dysfunctional platelets with coagulation cascades aggravates clotting events and thrombus formation. Furthermore, mitochondrial oxidative stress may contribute to microbiota dysbiosis, altering coagulation pathways and fueling the inflammatory/oxidative response leading to the vicious cycle of events. Here, we discuss various cellular and systemic incidents caused by SARS-CoV-2 that may critically impact intra and extracellular mitochondrial function, and contribute to the progression and severity of the disease. It is crucial to understand how these key modulators impact COVID-19 pathogenesis in the quest to identify novel therapeutic targets that may reduce fatal outcomes of the disease., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
34. Iron: Innocent bystander or vicious culprit in COVID-19 pathogenesis?
- Author
-
Edeas M, Saleh J, and Peyssonnaux C
- Subjects
- Betacoronavirus, COVID-19, Coronavirus Infections mortality, Cytokine Release Syndrome virology, Ferroptosis, Hepcidins physiology, Humans, Inflammation, Iron blood, Mitochondria pathology, Mitochondria physiology, Oxidative Stress, Pandemics, Pneumonia, Viral mortality, SARS-CoV-2, Coronavirus Infections pathology, Iron Overload virology, Pneumonia, Viral pathology
- Abstract
The coronavirus 2 (SARS-CoV-2) pandemic is viciously spreading through the continents with rapidly increasing mortality rates. Current management of COVID-19 is based on the premise that respiratory failure is the leading cause of mortality. However, mounting evidence links accelerated pathogenesis in gravely ill COVID-19 patients to a hyper-inflammatory state involving a cytokine storm. Several components of the heightened inflammatory state were addressed as therapeutic targets. Another key component of the heightened inflammatory state is hyper-ferritinemia which reportedly identifies patients with increased mortality risk. In spite of its strong association with mortality, it is not yet clear if hyper-ferritinemia in COVID-19 patients is merely a systemic marker of disease progression, or a key modulator in disease pathogenesis. Here we address implications of a possible role for hyper-ferritinemia, and altered iron homeostasis in COVID-19 pathogenesis, and potential therapeutic targets in this regard., (Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
35. From Donor to Patient: Collection, Preparation and Cryopreservation of Fecal Samples for Fecal Microbiota Transplantation.
- Author
-
Nicco C, Paule A, Konturek P, and Edeas M
- Abstract
Fecal Microbiota Transplantation (FMT) is suggested as an efficacious therapeutic strategy for restoring intestinal microbial balance, and thus for treating disease associated with alteration of gut microbiota. FMT consists of the administration of fresh or frozen fecal microorganisms from a healthy donor into the intestinal tract of diseased patients. At this time, in according to healthcare authorities, FMT is mainly used to treat recurrent Clostridium difficile . Despite the existence of a few existing stool banks worldwide and many studies of the FMT, there is no standard method for producing material for FMT, and there are a multitude of factors that can vary between the institutions. The main constraints for the therapeutic uses of FMT are safety concerns and acceptability. Technical and logistical issues arise when establishing such a non-standardized treatment into clinical practice with safety and proper governance. In this context, our manuscript describes a process of donor safety screening for FMT compiling clinical and biological examinations, questionnaires and interviews of donors. The potential risk of transmission of SARS-CoV-2 virus by the use of fecal microbiota for transplantation must be taken urgently into consideration. We discuss a standardized procedure of collection, preparation and cryopreservation of fecal samples through to the administration of material to patients, and explore the risks and limits of this method of FMT. The future success of medicine employing microbiota transplantation will be tightly related to its modulation and manipulation to combat dysbiosis. To achieve this goal, standard and strict methods need to be established before performing any type of FMT.
- Published
- 2020
- Full Text
- View/download PDF
36. Antioxidant Supplements and Oxidative Stress: The debate extends to the Middle East.
- Author
-
Saleh J, Edeas M, and Van Goor H
- Subjects
- Humans, Antioxidants therapeutic use, Dietary Supplements, Oxidative Stress drug effects
- Published
- 2019
- Full Text
- View/download PDF
37. Microbiota and Phage Therapy: Future Challenges in Medicine.
- Author
-
Paule A, Frezza D, and Edeas M
- Abstract
An imbalance of bacterial quantity and quality of gut microbiota has been linked to several pathologies. New strategies of microbiota manipulation have been developed such as fecal microbiota transplantation (FMT); the use of pre/probiotics; an appropriate diet; and phage therapy. The presence of bacteriophages has been largely underestimated and their presence is a relevant component for the microbiome equilibrium. As a promising treatment, phage therapy has been extensively used in Eastern Europe to reduce pathogenic bacteria and has arisen as a new method to modulate microbiota diversity. Phages have been selected and "trained" to infect a wide spectrum of bacteria or tailored to infect specific antibiotic resistant bacteria present in patients. The new development of genetically modified phages may be an efficient tool to treat the gut microbiota dysbiosis associated with different pathologies and increased production of bacterial metabolites and subsequently decrease systemic low-grade chronic inflammation associated with chronic diseases. Microbiota quality and mitochondria dynamics can be remodulated and manipulated by phages to restore the equilibrium and homeostasis of the system. Our aim is to highlight the great interest for phages not only to eliminate and control pathogenic bacterial infection but also in the near future to modulate the microbiota by adding new functions to selected bacteria species and rebalance the dynamic among phages and bacteria. The challenge for the medicine of tomorrow is to re-think and redesign strategies differently and far from our traditional thinking., Competing Interests: The authors declare no conflict of interest.
- Published
- 2018
- Full Text
- View/download PDF
38. Microbiota Quality and Mitochondrial Activity Link with Occurrence of Muscle Cramps in Hemodialysis Patients using Citrate Dialysate: A Pilot Study.
- Author
-
Durand PY, Nicco C, Serteyn D, Attaf D, and Edeas M
- Subjects
- Aged, Aged, 80 and over, Dysbiosis blood, Dysbiosis microbiology, Dysbiosis therapy, Female, Humans, Male, Mitochondria, Muscle pathology, Muscle Cramp, Pilot Projects, Bacteria classification, Bacteria growth & development, Citric Acid blood, Gastrointestinal Microbiome, Kidney Failure, Chronic blood, Kidney Failure, Chronic microbiology, Kidney Failure, Chronic therapy, Mitochondria, Muscle metabolism, Renal Dialysis
- Abstract
Background/aims: Hemodialysis-associated muscle cramp (HAMC) is a common complication under citrate dialysate (CD) occurring in 30% of cases. Our objectives were to assess the gut microbiota quality, mitochondrial activity, and to investigate their possible relationship with HAMC., Methods: Ten end-stage renal disease patients (78.9 ± 2.1 years) treated by hemodialysis (HD) with CD were enrolled and then classified according to the frequency of HAMCs: "frequent HAMCs group" (n = 5) and "absence of HAMCs group" (n = 5). Gut microbiota quality, mitochondrial activity, and some markers of oxidative stress (OS) were investigated., Results: In patients with cramps, gut microbiota diversity seemed lower and some genera including Helicobacter, Lachnospira, Roseburia, and Haemophilus seemed over-expressed, a significant increase of citratemia and significant lowering mitochondrial function were observed. No difference was observed on the OS markers., Conclusion: This first clinical study revealed a possible dysbiosis of microbiota and a mitochondrial dysfunction into HD patients with cramps under CD compared to patients without cramp., (© 2018 S. Karger AG, Basel.)
- Published
- 2018
- Full Text
- View/download PDF
39. Microbiota-mitochondria inter-talk: consequence for microbiota-host interaction.
- Author
-
Saint-Georges-Chaumet Y and Edeas M
- Subjects
- Animals, Host-Pathogen Interactions, Humans, Mitochondria metabolism, Reactive Oxygen Species toxicity, Signal Transduction, Ecosystem, Gastrointestinal Microbiome immunology, Gastrointestinal Microbiome physiology, Intestinal Mucosa immunology, Intestinal Mucosa microbiology, Mitochondria physiology, Reactive Oxygen Species metabolism
- Abstract
New discoveries in metagenomics and clinical research have highlighted the importance of the gut microbiota for human health through the regulation of the host immune response and energetic metabolism. The microbiota interacts with host cells in particular by intermingling with the mitochondrial activities. This mitochondria-microbiota cross-talk is intriguing because mitochondria share many common structural and functional features with the prokaryotic world. Several studies reported a correlation between microbiota quality and diversity and mitochondrial function. The mitochondrial production of reactive oxygen species (ROS) plays an important role during the innate immune response and inflammation, and is often targeted by pathogenic bacteria. Data suggest that excessive mitochondrial ROS production may affect ROS signaling induced by the microbiota to regulate the gut epithelial barrier. Finally, the microbiota releases metabolites that can directly interfere with the mitochondrial respiratory chain and ATP production. Short chain fatty acids have beneficial effects on mitochondrial activity. All these data suggest that the microbiota targets mitochondria to regulate its interaction with the host. Imbalance of this targeting may result in a pathogenic state as observed in numerous studies. The challenge to find new treatments will be to find strategies to modulate the quality and diversity of the microbiota rather than acting on microbiota metabolites and microbiota-related factors., (© FEMS 2015. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2016
- Full Text
- View/download PDF
40. Targeting microbiota-mitochondria inter-talk: Microbiota control mitochondria metabolism.
- Author
-
Saint-Georges-Chaumet Y, Attaf D, Pelletier E, and Edeas M
- Subjects
- Fatty Acids metabolism, Humans, Hydrogen Sulfide metabolism, Nitric Oxide metabolism, Oxidation-Reduction, Reactive Oxygen Species metabolism, Gastrointestinal Microbiome physiology, Gastrointestinal Tract microbiology, Mitochondria metabolism, Oxidative Stress physiology
- Abstract
Our aim is to highlight the subtle relationship that exists between microbiota and mitochondria. Microbiota targets mitochondria by modulating the Reactive Oxygen Species (ROS) production and the mitochondrial activity through interactions with toxins, proteins or other metabolites released by gut microbiota. The intriguing relationship that exists between mitochondria and microbiota is strengthened by the probable prokaryotic origin of mitochondria. Emerging data implicates a role for ROS, nitric oxide, Short Chain Fatty Acids and hydrogen sulfide in the cross-talk between microbiota - mitochondria and REDOX signaling. Several studies have shown that microbiota act and modulate mitochondrial activity, and use it as a relay to strengthen host-microbiotal interaction. This modulation depends on the gut bacterial strain quality and diversity to increase its pathogenic versus beneficial effects. Furthermore, based on conclusions from new studies, it is possible that microbiota can directly interact with the host cell gene expression by favoring bacterial and mitochondrial DNA insertion in the nuclear genome. The emerging knowledge of mitochondria-microbiota interaction may be of great importance to better understand the mechanism of mitochondrial and metabolic diseases, and the syndromes associated with change in quality and quantity of microbiotal species. We suggest that microbiota via mitochondrial modulation influence cell homeostasis and metabolism. The challenge will be to find strategies to modulate the quality and diversity of microbiota rather than acting on microbiota metabolites and microbiota related factors. The medicine of tomorrow will be completely personalized. Firstly there will be a test to show the quality, quantity and diversity of microbiota, and secondly a preventive or therapeutic strategy will be administrated (probiotics, diet, prodrug or fecal transplantation). The era of digital medicine is here.
- Published
- 2015
41. Mitochondrial medicine. Preface.
- Author
-
Weissig V and Edeas M
- Subjects
- Animals, Humans, Mitochondria ultrastructure, Medicine, Mitochondria physiology
- Published
- 2015
- Full Text
- View/download PDF
42. Erratum.
- Author
-
Weissig V and Edeas M
- Published
- 2015
- Full Text
- View/download PDF
43. Targeting mitochondria: strategies, innovations and challenges: The future of medicine will come through mitochondria.
- Author
-
Edeas M and Weissig V
- Subjects
- Humans, Drug Delivery Systems methods, Mitochondria drug effects, Mitochondrial Diseases drug therapy, Molecular Medicine methods
- Abstract
Mitochondrial dysfunction has been associated with the aging process and a large variety of human disorders, such as cardiovascular and neurodegenerative diseases, cancer, migraine, infertility, kidney and liver diseases, toxicity of drugs and many more. It is well recognized that the physiological role of mitochondria widely exceeds that of solely being the biochemical power plant of our cells. Over the recent years, mitochondria have become an interesting target for drug therapy, and the research field aimed at "targeting mitochondria" is active and expanding as witnessed by this already third edition of the world congress on targeting mitochondria. It is becoming a necessity and an urge to know why and how to target mitochondria with bioactive molecules and drugs in order to treat and prevent mitochondria-based pathologies and chronic diseases. This special issue covers a variety of new strategies and innovations as well as clinical applications in mitochondrial medicine., (Copyright © 2013 © Elsevier B.V. and Mitochondria Research Society. All rights reserved. Published by Elsevier B.V. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
44. Strategies to target mitochondria and oxidative stress by antioxidants: key points and perspectives.
- Author
-
Edeas M
- Subjects
- Antioxidants physiology, Antioxidants therapeutic use, Clinical Trials as Topic, Humans, Male, Mitochondria metabolism, Oxidative Stress physiology, Reactive Oxygen Species metabolism, Antioxidants pharmacology, Mitochondria drug effects, Molecular Targeted Therapy, Oxidative Stress drug effects
- Abstract
For several decades, many antioxidants studies have emphasized the marked disparity between the beneficial effect of the antioxidants shown in preclinical studies and their inability to show beneficial effects in clinical trials. Besides, it is not uncommon to find highly contradictory clinical results, which may explain why consumers are less enthusiastic for antioxidant uses. This perspective article aims to highlights the critical role of Reactive Oxygen Species (ROS) and antioxidants, the potential mechanisms that might account for these discrepancies in clinical trials and some strategies to target oxidative stress and mitochondria by antioxidants. We need urgently to set up standard methods to evaluate antioxidants and oxidative stress in human and in particular at mitochondria level. The determination of what the basal level of ROS is in normal human may be used to identify pathologic ROS levels in patients and ultimately guide antioxidants treatment.
- Published
- 2011
- Full Text
- View/download PDF
45. Polyphenols and human health: a prospectus.
- Author
-
Visioli F, De La Lastra CA, Andres-Lacueva C, Aviram M, Calhau C, Cassano A, D'Archivio M, Faria A, Favé G, Fogliano V, Llorach R, Vitaglione P, Zoratti M, and Edeas M
- Subjects
- Animals, Antioxidants pharmacokinetics, Biological Availability, Biomarkers analysis, Curcumin chemistry, Diet, Food Analysis, Free Radicals, Humans, Lythraceae chemistry, Metabolomics methods, Mitochondria metabolism, Polyphenols pharmacokinetics, Wine analysis, Antioxidants pharmacology, Polyphenols pharmacology
- Abstract
The lay press often heralds polyphenols as panacea for all sorts of diseases. The rationale is that their antioxidant activity would prevent free radical damage to macromolecules. However, basic and clinical science is showing that the reality is much more complex than this and that several issues, notably content in foodstuff, bioavailability, or in vivo antioxidant activity are yet to be resolved. We summarize the recent findings concerning the effects of polyphenols on human health, analyze the current limitations at pitfalls, and propose future directions for research.
- Published
- 2011
- Full Text
- View/download PDF
46. [Anti-oxidants, controversies and perspectives: how can the failure of clinical studies using anti-oxidants be explained?].
- Author
-
Edeas M
- Subjects
- Animals, Antioxidants pharmacokinetics, Antioxidants pharmacology, Biological Availability, Clinical Trials as Topic methods, Dose-Response Relationship, Drug, Forecasting, Glycosylation drug effects, Humans, Mitochondria drug effects, Mitochondria physiology, Models, Biological, Nutrigenomics, Oxidation-Reduction, Oxidative Stress drug effects, Reactive Oxygen Species toxicity, Research Design, Treatment Failure, Antioxidants therapeutic use
- Abstract
Since several decades anti-oxidants have been much studied, and scientists have tried to prove the preventive and curative effects in many chronic diseases. However, it is not uncommon to find highly contradictory clinical results, which may explain that consumers are less enthusiastic for anti-oxidants food supplements. First of all, definitions should be reviewed, such as that of free radicals (FR); all of them are not toxic. Some of them, such as nitric oxide, are necessary for the proper physiological functioning of the body, and eliminating them would be a mistake! However, other reactive oxygen species (ROS), which are not FR, are toxic, such as hydrogen peroxide. We have also redefined the oxidative stress, which it is not only the result of an imbalance between oxidants and anti-oxidants, but also the consequence of imbalance in the cellular redox status. The mechanisms of action, bioavailability, synergy and methods to determine the level of anti-oxidants are very sensitive topics, and it is crucial to study them if we want to obtain reliable clinical studies. Given the failure of clinical studies about anti-oxidant, we try to explain strategies which should be followed. First of all, the nature of the anti-oxidant is important; and an anti-oxidant from a natural origin must be preferred. Then, we proposed that the dose-effect was certainly responsible for the failure of tests. Indeed, doses administered in the studies was either too weak to obtain significant results, or too high, becoming pro-oxidative and eliminating the basal concentration of ROS (physiological role). Involvement of mitochondria and glycation are particularly discussed. Nutrigenomics and nutrigenetics are also discussed, which study the interactions between genetics and nutrition. Genetic polymorphism can explain the variable absorption of micronutrients. This concept leads to a truth believed by all scientists, namely the need to provide the right anti-oxidant, in adequate quantity, at the right place, at the right time and for a particular individual. To increase the anti-oxidant capacity of the body, the exogenous intake of anti-oxidants must be increased or the endogenous synthesis of anti-oxidants (SOD, GPX, GSH) must be stimulated. Targeting mitochondria and increasing their overall anti-oxidant defence system will be a challenge. Increasing the bioavailability of anti-oxidants and studying their passage through the blood-brain barrier must be also taken in consideration.
- Published
- 2009
- Full Text
- View/download PDF
47. First International Conference on Therapies of Obesity: perspectives for pharmaceutical and natural products (Paris Anti Obesity Therapies 2006), May 18-19 2006, Institut Pasteur, Paris, France.
- Author
-
Edeas M
- Subjects
- Animals, Dairy Products, Humans, Obesity diet therapy, Anti-Obesity Agents therapeutic use, Obesity drug therapy, Obesity prevention & control
- Published
- 2006
48. Protective effects of the lipophilic redox conjugate tocopheryl succinyl-ethyl ferulate on HIV replication.
- Author
-
Edeas MA, Claise C, Vergnes L, Khalfoun Y, Barthelemy S, Labidalle S, and Lindenbaum A
- Subjects
- Caffeic Acids pharmacology, Cell Line, Cells, Cultured, Glutathione metabolism, HIV Core Protein p24 analysis, HIV-1 drug effects, Humans, Macrophages drug effects, Monocytes cytology, Vitamin A pharmacology, Vitamin E pharmacology, Coumaric Acids pharmacology, HIV-1 physiology, Lipid Peroxidation drug effects, Macrophages physiology, Macrophages virology, Virus Replication drug effects, Vitamin A analogs & derivatives
- Abstract
Previously, we demonstrated that ferulate ethyl and tocopherol reduced HIV replication. In this study, we investigate whether the conjugation of both compounds (O-tocopheryl succinyl O-ethyl ferulate) can increase HIV inhibition. We show here for the first time that O-tocopheryl succinyl O-ethyl ferulate inhibits 80% of HIV replication (HIV-1 acute infection and HIV transmission), inhibits cell lipoperoxidation and prevents cellular glutathione consumption. Compared to ferulate ethyl and tocopheryl succinyl, O-tocopheryl succinyl O-ethyl ferulate inhibits more HIV replication. This may be due in part to the great increase in the lipophilicity of this compound.
- Published
- 1997
- Full Text
- View/download PDF
49. Clastogenic factors in plasma of HIV-1 infected patients activate HIV-1 replication in vitro: inhibition by superoxide dismutase.
- Author
-
Edeas MA, Emerit I, Khalfoun Y, Lazizi Y, Cernjavski L, Levy A, and Lindenbaum A
- Subjects
- Humans, Interleukin-2 pharmacology, Mutagens metabolism, Phytohemagglutinins pharmacology, Acquired Immunodeficiency Syndrome blood, HIV-1 physiology, Mutagens pharmacology, Superoxide Dismutase pharmacology, Virus Replication
- Abstract
The frequent neoplastic disorders present in HIV-infected patients and the implication of oxidative stress in AIDS-Kaposi's sarcoma pathogenesis prompted us to study whether the mechanisms implicated in genotoxic effects of clastogenic factors (CFs) (i.e., chromosome damaging materials released by cells under conditions of oxidant stress) can play a role in HIV-1 expression and whether exogenous superoxide dismutase can inhibit the clastogenic and HIV-inducing effects of CFs. CFs were found in the plasma of all HIV-1 infected patients (n = 21) of this study group, in asymptomatic (CDC II) as well as in symptomatic patients (CDC IV). In addition to their chromosome damaging effect, CFs are able to upregulate HIV-1 expression in U1 cells and in PBMCs activated with PHA and IL2 at all time points (p < .05). Their formation, therefore, is an early event in the disease. It occured despite antiviral medication in these patients. Superoxide dismutase inhibited the clastogenic and the viral inducing effects (p < .05). On the basis of our findings, association of SOD mimetics or superoxide scavengers with antiviral drugs may be a new therapeutic approach. This polytherapy, if started early enough after infection, may prolong the latency period and limit the emergence of drug-resistant viral strains.
- Published
- 1997
- Full Text
- View/download PDF
50. Immunocytochemical study of uptake of exogenous carrier-free copper-zinc superoxide dismutase by peripheral blood lymphocytes.
- Author
-
Edeas MA, Peltier E, Claise C, Khalfoun Y, and Lindenbaum A
- Subjects
- Biological Transport, Humans, Immunohistochemistry, Lymphocytes cytology, Cell Membrane metabolism, Lymphocytes metabolism, Superoxide Dismutase metabolism
- Abstract
We recently demonstrated that exogenous copper-zinc superoxide dismutase (SOD) reduced HIV replication in tumor necrosis factor alpha activated chronically HIV-infected promonocytic U1 cell line and in peripheral blood mononuclear cells coculture. However, whether exogenous SOD penetrates the cellular membrane or acts extracellularly has been remained controversial. SOD has been considered as not to penetrate the cellular membrane because of its high molecular weight, thus the main site of action is presumed to be extracellular. In order to determine whether exogenous SOD penetrates inside the cell, we utilized a gentle immunocytochemical method to detect Mn and Cu,Zn SOD in peripheral blood lymphocytes incubated with various concentrations of exogenous carrier-free Cu,Zn SOD without prior permeabilization of cell membranes. After 24 hrs. the total SOD activity and immunocytochemical studies were performed. Here we demonstrate clearly that a large amount of carrier-free Cu,Zn SOD, added exogenously, penetrates the cellular membrane and increases total SOD activity.
- Published
- 1996
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.